New steroids and steroid–longacting β₂agonist combinations

Author：

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.13, Iss.4, 2003-04, pp. : 557-561

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combinations of a long-acting β₂ agonist; is it BI-1744-CL?

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 11, 2007-11 ,pp. : 1401-1404

Informa Healthcare

Access to resources Recommend Favorite

Indacaterol: a new long-acting β₂-agonist in the management of chronic obstructive pulmonary disease

By Steiropoulos Paschalis Papanas Nikolaos Nena Evangelia Bouros Demosthenes

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1015-1029

Informa Healthcare

Access to resources Recommend Favorite

New long-acting β₂-agonists

Expert Opinion on Therapeutic Patents, Vol. 14, Iss. 9, 2004-09 ,pp. : 1385-1388

Informa Healthcare

Access to resources Recommend Favorite

Long-acting β₂ agonists

By Norman Peter

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 1, 2006-01 ,pp. : 99-104

Informa Healthcare

Access to resources Recommend Favorite

The Impact of Nonadherence to Inhaled Long-Acting β 2 -Adrenoceptor Agonist/Corticosteroid Combination Therapy on Healthcare Costs in Difficult-to-Control Asthma

By O'Neill Ciaran Gamble Jacqui Lindsay John T. Heaney Liam G.

Pharmaceutical Medicine, Vol. 25, Iss. 6, 2011-12 ,pp. : 379-385

Adis International

Access to resources Recommend Favorite